156 related articles for article (PubMed ID: 29581112)
1. Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose.
Eschenauer GA; Carver PL; Patel TS; Lin SW; Klinker KP; Pai MP; Lam SW
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581112
[TBL] [Abstract][Full Text] [Related]
2. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.
Wilson AG; Micek ST; Ritchie DJ
Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections.
Lee I; Morales KH; Zaoutis TE; Fishman NO; Nachamkin I; Lautenbach E
Am J Infect Control; 2010 Nov; 38(9):740-5. PubMed ID: 20542354
[TBL] [Abstract][Full Text] [Related]
4. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
5. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
6. Impact of high MIC of fluconazole on outcomes of Candida glabrata bloodstream infection: a retrospective multicenter cohort study.
Ko JH; Peck KR; Jung DS; Lee JY; Kim HA; Ryu SY; Jung SI; Joo EJ; Cheon S; Kim YS; Kim SW; Cho SY; Ha YE; Kang CI; Chung DR; Lee NY; Song JH
Diagn Microbiol Infect Dis; 2018 Oct; 92(2):127-132. PubMed ID: 29929855
[TBL] [Abstract][Full Text] [Related]
7. Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.
Puig-Asensio M; Fernández-Ruiz M; Aguado JM; Merino P; Lora-Pablos D; Guinea J; Martín-Dávila P; Cuenca-Estrella M; Almirante B
Antimicrob Agents Chemother; 2016 Jun; 60(6):3291-300. PubMed ID: 26976872
[TBL] [Abstract][Full Text] [Related]
8. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study.
Torres HA; Kontoyiannis DP; Rolston KV
Support Care Cancer; 2004 Jul; 12(7):511-6. PubMed ID: 14986077
[TBL] [Abstract][Full Text] [Related]
9. Take control over your fluconazole prescriptions: the growing importance of Candida glabrata as an agent of candidemia in Brazil.
Pasqualotto AC; Zimerman RA; Alves SH; Aquino VR; Branco D; Wiltgen D; do Amaral A; Cechinel R; Colares SM; da Rocha IG; Severo LC; Sukiennik TC
Infect Control Hosp Epidemiol; 2008 Sep; 29(9):898-9. PubMed ID: 18785850
[No Abstract] [Full Text] [Related]
10. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients.
Cohen Y; Karoubi P; Adrie C; Gauzit R; Marsepoil T; Zarka D; Clec'h C
Crit Care Med; 2010 Mar; 38(3):826-30. PubMed ID: 20042858
[TBL] [Abstract][Full Text] [Related]
11. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.
Rodríguez-Tudela JL; Almirante B; Rodríguez-Pardo D; Laguna F; Donnelly JP; Mouton JW; Pahissa A; Cuenca-Estrella M
Antimicrob Agents Chemother; 2007 Oct; 51(10):3599-604. PubMed ID: 17646421
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection: potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance.
Lee I; Zaoutis TE; Fishman NO; Morales KH; Nachamkin I; Lautenbach E
Am J Infect Control; 2010 Aug; 38(6):456-60. PubMed ID: 20371135
[TBL] [Abstract][Full Text] [Related]
13. Candida glabrata fungaemia in intensive care units.
Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
[TBL] [Abstract][Full Text] [Related]
14. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines.
Garey KW; Pai MP; Suda KJ; Turpin RS; Rege MD; Mingo DE; Bearden DT
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):919-27. PubMed ID: 17286303
[TBL] [Abstract][Full Text] [Related]
15. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.
Pfaller MA; Messer SA; Boyken L; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2003 May; 41(5):2176-9. PubMed ID: 12734273
[TBL] [Abstract][Full Text] [Related]
16. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
17. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial.
Magill SS; Swoboda SM; Shields CE; Colantuoni EA; Fothergill AW; Merz WG; Lipsett PA; Hendrix CW
Ann Surg; 2009 Apr; 249(4):657-65. PubMed ID: 19300221
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.
Lee I; Fishman NO; Zaoutis TE; Morales KH; Weiner MG; Synnestvedt M; Nachamkin I; Lautenbach E
Arch Intern Med; 2009 Feb; 169(4):379-83. PubMed ID: 19237722
[TBL] [Abstract][Full Text] [Related]
19. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.
Magill SS; Shields C; Sears CL; Choti M; Merz WG
J Clin Microbiol; 2006 Feb; 44(2):529-35. PubMed ID: 16455909
[TBL] [Abstract][Full Text] [Related]
20. Candida glabrata fungemia: experience in a tertiary care center.
Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA
Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
